GlassScriptPhysician profile
Justin Kappel
NPI 1689105850
$5,357.83
in general payments reported to CMS, 2019-2025
46 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $1,085 · 2023: $1,163 · 2024: $1,537 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.73 | 2021-2025 | |
| Novo Nordisk INC | $763.12 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $297.77 | 2022-2025 | |
| Lilly USA, LLC | $296.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $225.94 | 2024 | Inspire |
| Abbott Laboratories | $211.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Neos Therapeutics, LP | $192.10 | 2022-2023 | Adzenys Xr-Odt |
| Astellas Pharma US INC | $167.30 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $140.69 | 2021-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $134.41 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.24 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $125.28 | 2022-2025 | Evenity, Prolia |
| Corium, LLC | $123.72 | 2022-2023 | Azstarys |
| Exact Sciences Corporation | $120.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.55 | 2021-2023 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $97.04 | 2022-2023 | |
| Tris Pharma INC | $94.77 | 2022-2024 | Dyanavel Xr |
| Dexcom, INC. | $77.70 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $74.20 | 2021-2022 | |
| Madrigal Pharmaceuticals | $71.88 | 2024-2025 | Resmetirom, Rezdiffra |
| Axsome Therapeutics, INC. | $69.95 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.35 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Idorsia Pharmaceuticals US INC | $55.85 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $52.91 | 2023-2025 | Farxiga, Airsupra |
| Gilead Sciences, INC. | $44.92 | 2025 | |
| Ironshore Pharmaceuticals INC. | $42.32 | 2022 | |
| Daiichi Sankyo INC. | $41.18 | 2022 | |
| Noven Therapeutics, LLC | $39.54 | 2023 | Xelstrym |
| Viiv Healthcare Company | $33.46 | 2022 | |
| Merck Sharp & Dohme LLC | $33.12 | 2021-2025 | Gardasil 9, Capvaxive |
| Boston Scientific Corporation | $29.50 | 2025 | General - Pain Management |
| Amneal Pharmaceuticals LLC | $28.98 | 2021-2022 | |
| Seqirus USA INC | $28.94 | 2024 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $25.63 | 2022 | |
| Saluda Medical Americas, INC. | $24.13 | 2024 | Evoke |
| Echosens North America, INC. | $22.59 | 2023 | Fibroscan |
| Impel Pharmaceuticals INC. | $21.87 | 2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $21.55 | 2021 | |
| Biotronik Nro, INC. | $20.32 | 2024 | Prospera |
| Otsuka America Pharmaceutical, INC. | $19.68 | 2022 | |
| Medtronic, INC. | $19.23 | 2024 | Interstim |
| Sumitomo Pharma America, INC. | $18.29 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $16.78 | 2024 | Nexletol |
| Philips North America LLC | $16.42 | 2024 | (5050) Extended Holter |
| Alexion Pharmaceuticals, INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Kappel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.